In 2020, the European Medicines Agency (EMA) published the outcome of a major, multi-stakeholder initiative led by the European Society for Organ Transplantation (ESOT) to modernise the regulatory framework for innovative therapies in kidney transplantation. This initiative, launched at the request of the EMA, addressed a critical scientific gap: the existing CHMP guideline on solid organ transplantation (2008), had become misaligned with advances in transplant biology, immunology, and clinical trial methodology. In particular, the continued reliance on outdated and insufficiently sensitive endpoints limited the field’s ability to accurately capture long-term graft outcomes and impeded the development and regulatory evaluation of novel immunosuppressive strategies. Over the past decade, the global transplant community has mobilised an exceptional level of scientific collaboration to overcome these limitations. By integrating expertise from clinicians, translational scientists, statisticians, and regulators, this effort has fundamentally re-examined how efficacy is defined and measured in kidney transplantation. A central objective has been to replace short-term, surrogate markers of uncertain relevance with endpoints that are both mechanistically grounded and predictive of long-term graft survival.
This work has culminated in the development of the iBox Scoring System, spearheaded by the Paris Transplant Group, led by Alexandre Loupy, in collaboration with a large international network of transplant centres. The iBox represents a major scientific advance: a rigorously derived and extensively validated prognostic model that integrates multidimensional data – including kidney function, proteinuria, donor-specific antibodies, and histopathological findings – into a unified, dynamic risk score. By leveraging large-scale, high-quality longitudinal datasets, the iBox captures the complex, multifactorial nature of allograft failure and enables individualised prediction of long-term outcomes with high accuracy and reproducibility.
The qualification of iBox by the EMA as the first prognostic endpoint in transplantation constitutes a landmark achievement. It reflects not only regulatory acceptance but also strong scientific validation of its predictive performance and clinical relevance. Importantly, iBox is currently in the final stage of review by the U.S. Food and Drug Administration (FDA) as a potential surrogate endpoint, which, if confirmed, would further establish its transatlantic regulatory credibility.
The scientific and clinical implications are substantial. The availability of a validated surrogate endpoint grounded in robust prognostic modelling (such as iBox) enables a paradigm shift in trial design, allowing for more sensitive detection of treatment effects and substantially shorter study durations. This is particularly critical in transplantation, where traditional endpoints require extended follow-up to demonstrate clinical benefit. By improving statistical efficiency and reducing uncertainty, iBox has the potential to accelerate therapeutic innovation while maintaining rigorous evidentiary standards.
More broadly, this achievement exemplifies the power of data-driven, collaborative science to address complex clinical challenges. It highlights the capacity of the (European) transplant community to generate high-quality evidence, translate it into clinically meaningful tools, and engage effectively with regulatory bodies. As such, the development and qualification of iBox not only advance the science of transplantation but also establish a new benchmark for endpoint innovation in clinical research.
Readings:
https://bmjgroup.com/transforming-kidney-transplant-trials/
https://www.sciencedirect.com/science/article/pii/S1600613523004161#:~:text=iBOX%20is%20a%20risk%20prediction,high%2Dres%20image%20(463KB)